Pfizer (NYSE:PFE) Shares Down 2.4% – Time to Sell?

Pfizer Inc. (NYSE:PFE) shares dropped 2.4% during mid-day trading on Monday . The company traded as low as $23.62 and last traded at $23.74. Approximately 58,429,589 shares were traded during trading, an increase of 36% from the average daily volume of 42,859,461 shares. The stock had previously closed at $24.32.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer is being highlighted as an undervalued dividend payer, with articles pointing to its unusually high yield and bargain-like valuation relative to large-cap healthcare peers. 2 Dirt Cheap Healthcare Stocks to Buy in July
• Positive Sentiment: Pfizer also received coverage suggesting its stock could be attractive after IBRANCE won a new FDA approval, which may support confidence in the company’s oncology franchise. Is Pfizer (PFE) Undervalued After IBRANCE Won A New FDA Approval?
• Neutral Sentiment: Pfizer is attracting investor attention, but that appears tied more to its high profile and dividend appeal than to a clear near-term catalyst. Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: JPMorgan lowered its price target on Pfizer to $28 from $30 while keeping a neutral rating, signaling caution but not a full bearish call. Pfizer price target lowered by JPMorgan
• Negative Sentiment: Several recent commentaries warn that Pfizer’s dividend yield may reflect investor skepticism about growth and suggest the payout could be riskier than it looks. Opinion: Pfizer’s Dividend Is Riskier Than You Might Think
• Negative Sentiment: Another article said Pfizer’s growth story is facing questions as pipeline and leadership doubts mount, which likely adds to pressure on the shares. Pfizer’s growth story faces a wait as pipeline and leadership doubts mount

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Monday. UBS Group reaffirmed a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, May 27th. Bank of America decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Guggenheim upped their target price on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Finally, Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target for the company in a research report on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $28.56.

Pfizer Stock Down 0.1%

The business has a 50-day simple moving average of $25.51 and a two-hundred day simple moving average of $26.21. The stock has a market capitalization of $137.05 billion, a P/E ratio of 18.36 and a beta of 0.35. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same period last year, the business earned $0.92 earnings per share. The business’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Institutional Trading of Pfizer

Large investors have recently added to or reduced their stakes in the company. Vermillion Wealth Management Inc. grew its position in Pfizer by 19.4% during the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 382 shares during the last quarter. Triad Wealth Partners LLC raised its position in Pfizer by 1.9% in the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares during the last quarter. Eagle Capital Management LLC boosted its stake in Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after purchasing an additional 390 shares in the last quarter. ETF Store Inc. grew its holdings in shares of Pfizer by 3.8% during the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after purchasing an additional 396 shares during the last quarter. Finally, Delta Financial Advisors LLC grew its holdings in shares of Pfizer by 1.6% during the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock worth $709,000 after purchasing an additional 398 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.